Genomma Lab InternacionalB de CV (FRA:GEKA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GEKA Genomma Lab Internacional SAB de CV FRA:GEKA
66 GF Score
Price €0.74
GF Value €0.85
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:GEKA
66GF Score
Genomma Lab Internacional SAB de CV FRA:GEKA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genomma Lab InternacionalB de CV (FRA:GEKA) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of €0.74 is trading 13.5% below its estimated GF Value™ of €0.85.

Key valuation signals for FRA:GEKA:

  • Dividends Received:
  • GF Value™: €0.85 vs. price of €0.74 (13.5% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the FRA:GEKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USALABB:Mexico
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for FRA:GEKA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.74
Price
€0.85
GF Value